The U.S. Patent and Trademark Office issued a new patent to iBio, covering the company’s rights for the use of endostatin-related peptides with therapeutic potential in a number of fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis (IPF). The patent, US 9,365,616, is titled “Use of Endostatin Peptides for the Treatment…
iBio Receives Patent on Endostatin-Related Peptides with Potential to Treat IPF
Pulmatrix, a clinical stage biopharmaceutical company, recently released an animated life sciences video describing their new dry powder inhaler system called Isperse for lung disease patients.
OFEV (nintedanib) is effective for a wide range of idiopathic pulmonary fibrosis (IPF) patients according to Boehringer Ingelheim, the company that developed the drug.
After reading a story in a newspaper, Cloyd Goley of Farmersville, Ohio, who has pulmonary fibrosis, felt newly hopeful. The article, published in the Dayton Daily News, told the story of the Rev. Joseph Kyles, a Chicago minister with  pulmonary fibrosis who was able to return to his work after undergoing a double-lung transplant. “It’s…
Patient stratification to deliver personalized medicine has become a routine practice in oncology that may be of great help in understanding and managing pulmonary diseases, such as idiopathic pulmonary fibrosis (IPF). Supported by a deep understanding of a disease,  stratification is a process that categorizes patients into subgroups according to disease progression,…
Doctors rarely see patients with symptoms of both pulmonary fibrosis and emphysema, but those who do quickly learn that these patients chart a very different clinical course than those with either condition. A case study by researchers at  Deccan College of Medical Sciences in India and the University of Florida underscores this, detailing a patient with combined pulmonary fibrosis…
Global Blood Therapeutics is initiating a Phase 2a clinical trial to assess its oral drug GBT440, an investigational hemoglobin modifier, as a daily treatment for idiopathic pulmonary fibrosis (IPF) and hypoxemia. Hypoxemia, or low blood oxygen levels, results in an insufficient amount of oxygen reaching the tissues (hypoxia). It is a leading cause of clinical decline in IPF…
https://www.youtube.com/watch?v=qLrR8QNa-E4 Pulmonary fibrosis is a lung condition that causes scarring of the lung tissue which results in difficulty breathing. With this video shared by the Royal Society of Medicine, listen in on a lecture by Dr. Melissa Wickremasinghe about living with pulmonary fibrosis and why the disease…
https://www.youtube.com/watch?v=sE9RG_srEBY Pulmonary fibrosis is a lung condition that causes scarring of the lung tissue, which results in difficulties in breathing. With this video, shared by the Royal Society of Medicine, you can watch a lecture by Julia Bott who talks about the benefits of…
Bellerophon Therapeutics recently announced that the Phase 3 INOvation-1 clinical trial evaluating the safety and efficacy of the INOpulse delivery of nitric oxide (NO) in patients with pulmonary arterial hypertension (PAH) has enrolled its first patient. In addition, the company is developing two other INOpulse devices, which may be used to treat patients…
